Genomic Health, Inc. (NASDAQ:GHDX) CFO Sells $1,813,000.00 in Stock

Share on StockTwits

Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 25,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $72.52, for a total value of $1,813,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

G Bradley Cole also recently made the following trade(s):

  • On Monday, August 12th, G Bradley Cole sold 60,000 shares of Genomic Health stock. The shares were sold at an average price of $73.31, for a total value of $4,398,600.00.
  • On Tuesday, July 9th, G Bradley Cole sold 6,471 shares of Genomic Health stock. The shares were sold at an average price of $57.08, for a total value of $369,364.68.

NASDAQ:GHDX traded up $0.37 during trading hours on Wednesday, reaching $72.98. The company’s stock had a trading volume of 316,158 shares, compared to its average volume of 557,530. The stock has a 50 day moving average price of $72.85 and a two-hundred day moving average price of $65.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.74 and a current ratio of 5.74. The company has a market capitalization of $2.68 billion, a P/E ratio of 69.50 and a beta of 1.00. Genomic Health, Inc. has a 12 month low of $50.77 and a 12 month high of $92.18.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.07. Genomic Health had a return on equity of 19.51% and a net margin of 11.69%. The business had revenue of $114.14 million for the quarter, compared to analysts’ expectations of $110.78 million. During the same quarter last year, the firm earned $0.23 EPS. The business’s revenue for the quarter was up 19.4% on a year-over-year basis. As a group, analysts predict that Genomic Health, Inc. will post 1.51 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. increased its position in shares of Genomic Health by 166.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock worth $55,000 after purchasing an additional 493 shares in the last quarter. Manchester Capital Management LLC purchased a new position in Genomic Health during the 1st quarter worth $56,000. Point72 Asset Management L.P. purchased a new position in Genomic Health during the 2nd quarter worth $93,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Genomic Health by 29.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock worth $112,000 after buying an additional 441 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. increased its position in Genomic Health by 12.7% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,301 shares of the medical research company’s stock valued at $192,000 after buying an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 95.36% of the company’s stock.

GHDX has been the topic of a number of recent research reports. Barclays raised Genomic Health from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $45.00 to $72.00 in a research report on Tuesday, July 30th. Zacks Investment Research upgraded Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 price objective for the company in a report on Wednesday, July 31st. ValuEngine downgraded Genomic Health from a “buy” rating to a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. raised shares of Genomic Health from an “underweight” rating to a “neutral” rating and upped their price objective for the stock from $60.00 to $72.00 in a research note on Monday, July 29th. Finally, Deutsche Bank dropped their target price on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating on the stock in a report on Thursday, May 30th. Ten equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $69.86.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

See Also: How to build a Fibonacci channel

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.